ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Oral Delivery Systems for Food-Derived Bioactive Peptides: Enhancing Stability, Bioavailability, and Health Benefits.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Food-derived bioactive peptides (FBPs) represent a promising class of nutraceuticals for the prevention and management of chronic diseases due to their diverse bioactivities and high biocompatibility; however, their therapeutic potential is severely limited by low oral bioavailability resulting from instability during processing, sensory drawbacks such as bitterness, and extensive gastrointestinal degradation. This review systematically outlines the major bottlenecks hindering the oral delivery of FBPs, including sensitivity to environmental factors (temperature, pH, metal ions) and physiological barriers (enzymatic hydrolysis, mucus layer, and epithelial transport). To overcome these challenges, advanced delivery systems, such as nanoparticles (NPs), nanoemulsions (NEs), liposomes, hydrogels, and composite carriers, have been designed. These engineered systems have demonstrated enhanced bioactivity and targeted delivery in preclinical models of neuroprotection, anti-inflammatory therapy, metabolic regulation, and cancer treatment, often outperforming free peptides in terms of stability and intestinal absorption. However, establishing quantitative correlations between formulation parameters and in vivo peptide bioavailability remains a critical bottleneck. Future research should focus on rationally designed stimuli-responsive platforms grounded in intestinal physiology, supported by standardized frameworks for scalable manufacturing and safety evaluation. This work provides a comprehensive framework for advancing FBPs delivery platforms toward functional food and chronic disease management applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.